The Phase 3 PREVAIL Study Assessing the Efficacy and Safety of Subcutaneous Gefurulimab in Adults with Generalized Myasthenia Gravis: Trial in Progress (P7-11.021)
Provide an overview of PREVAIL, which is evaluating the efficacy and safety of gefurulimab in adults with anti-acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG).
Authors
- Alanna McEneny
- Tuan Vu (ORCID: https://orcid.org/0000-0003-0724-0210)
- Joachim Scholz (ORCID: https://orcid.org/0000-0003-2795-7278)
- Kelly Gwathmey (ORCID: https://orcid.org/0000-0002-7589-8826)
- Sanjay N. Rakhade
- J. A. Howard (ORCID: https://orcid.org/0000-0001-5020-9687)
- Annie M. Racine (ORCID: https://orcid.org/0000-0003-3857-6163)
- Chongbo Zhao (ORCID: https://orcid.org/0000-0002-0475-1798)
- Shulian Shang
- Alexandra Peláez-Rivas
Institutions
- University of North Carolina at Chapel Hill (US)
- Fudan University (CN)
- University of South Florida (US)
- AstraZeneca (Brazil) (BR)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208763
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00